Perry A. Karsen, Director at Jounce Therapeutics, Inc. (JNCE), bought 5,000 shares at $16.00 ($80K) on 2017-02-01, disclosed to the SEC on 2017-02-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| CELG | SELL | 2015-05-15 | $5.4M | — | Filing → |
| CELG | SELL | 2015-02-13 | $3.4M | — | Filing → |
| CELG | SELL | 2015-01-02 | $2.2M | — | Filing → |